recombinant protein subunit vaccine Search Results


recombinant spike protein subunit vaccines spikogen  (CinnaGen Co)
90
CinnaGen Co recombinant spike protein subunit vaccines spikogen
Recombinant Spike Protein Subunit Vaccines Spikogen, supplied by CinnaGen Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+protein+subunit+vaccine/recombinant+spike+protein+subunit+vaccines+spikogen/pmc10760503-23-34-41
Average 90 stars, based on 1 article reviews
recombinant spike protein subunit vaccines spikogen - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
sars-cov-2 protein subunit recombinant vaccine  (BIOFARMA Pharmaceutical)
90
BIOFARMA Pharmaceutical sars-cov-2 protein subunit recombinant vaccine
Schematic drawing of <t>SARS-CoV-2</t> representing the major virus components: spike glycoprotein (S), hemagglutinin-esterase dimer (HE), membrane protein (M), envelope protein (E), nucleocapsid, and genomic RNA. (Redrawn by the authors based on Figure 2 in Ref. ).
Sars Cov 2 Protein Subunit Recombinant Vaccine, supplied by BIOFARMA Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+protein+subunit+vaccine/sars+cov+2+protein+subunit+recombinant+vaccine/pmc08779282-128-2-8
Average 90 stars, based on 1 article reviews
sars-cov-2 protein subunit recombinant vaccine - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
recombinant spike protein subunit vaccine  (SK Bioscience Co Ltd)
90
SK Bioscience Co Ltd recombinant spike protein subunit vaccine
Ongoing clinical trials for novel vaccine compounds against infectious diseases in humans in phases 1–3 listed by the FDA by the November 1, 2021 ( https://www.clinicaltrials.gov/ )
Recombinant Spike Protein Subunit Vaccine, supplied by SK Bioscience Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+protein+subunit+vaccine/recombinant+spike+protein+subunit+vaccine/pmc08661323-39-6-15
Average 90 stars, based on 1 article reviews
recombinant spike protein subunit vaccine - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
recombinant subunit protein vaccine  (Profectus BioSciences Inc)
90
Profectus BioSciences Inc recombinant subunit protein vaccine
Coalition for Epidemic Preparedness Innovations Vaccine-Development Partnerships up to March 2019
Recombinant Subunit Protein Vaccine, supplied by Profectus BioSciences Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+protein+subunit+vaccine/recombinant+subunit+protein+vaccine/pmc07108492-3-11-0
Average 90 stars, based on 1 article reviews
recombinant subunit protein vaccine - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
recombinant denv vaccine  (Sanofi)
86
Sanofi recombinant denv vaccine
Coalition for Epidemic Preparedness Innovations Vaccine-Development Partnerships up to March 2019
Recombinant Denv Vaccine, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+protein+subunit+vaccine/bivalent+protein+recombinant+subunit+vaccine/pmc08673330-81-71-79
Average 86 stars, based on 1 article reviews
recombinant denv vaccine - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
veterinary subunit vaccine recombinant e2 protein  (Bayer AG)
90
Bayer AG veterinary subunit vaccine recombinant e2 protein
Coalition for Epidemic Preparedness Innovations Vaccine-Development Partnerships up to March 2019
Veterinary Subunit Vaccine Recombinant E2 Protein, supplied by Bayer AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+protein+subunit+vaccine/veterinary+subunit+vaccine+recombinant+e2+protein/pm18393606-27-2-15
Average 90 stars, based on 1 article reviews
veterinary subunit vaccine recombinant e2 protein - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Schematic drawing of SARS-CoV-2 representing the major virus components: spike glycoprotein (S), hemagglutinin-esterase dimer (HE), membrane protein (M), envelope protein (E), nucleocapsid, and genomic RNA. (Redrawn by the authors based on Figure 2 in Ref. ).

Journal: Vaccines

Article Title: A Narrative Review of COVID-19 Vaccines

doi: 10.3390/vaccines10010062

Figure Lengend Snippet: Schematic drawing of SARS-CoV-2 representing the major virus components: spike glycoprotein (S), hemagglutinin-esterase dimer (HE), membrane protein (M), envelope protein (E), nucleocapsid, and genomic RNA. (Redrawn by the authors based on Figure 2 in Ref. ).

Article Snippet: 83 , SARS-CoV-2 Protein Subunit Recombinant Vaccine , Biofarma , Protein subunit , Indonesia , 1/2 , NCT05067894 , Indonesia , 780 , November 2021–March 2022 , Safety (phase I) and immunogenicity (phase II) of the SARS-CoV-2 protein subunit recombinant vaccine..

Techniques:

SARS CoV-2 life cycle: (1) Binding and viral entry to the host cell via endocytosis; (2) release of viral genome; (3) translation and (4) replication of RNA genome; (5) transcription and translation of RNA into protein; (6) assembly and budding, followed by (7) mature virion formation; and (8) release of the new virion from the host cell. (Redrawn by the authors based on second figure in Ref. ).

Journal: Vaccines

Article Title: A Narrative Review of COVID-19 Vaccines

doi: 10.3390/vaccines10010062

Figure Lengend Snippet: SARS CoV-2 life cycle: (1) Binding and viral entry to the host cell via endocytosis; (2) release of viral genome; (3) translation and (4) replication of RNA genome; (5) transcription and translation of RNA into protein; (6) assembly and budding, followed by (7) mature virion formation; and (8) release of the new virion from the host cell. (Redrawn by the authors based on second figure in Ref. ).

Article Snippet: 83 , SARS-CoV-2 Protein Subunit Recombinant Vaccine , Biofarma , Protein subunit , Indonesia , 1/2 , NCT05067894 , Indonesia , 780 , November 2021–March 2022 , Safety (phase I) and immunogenicity (phase II) of the SARS-CoV-2 protein subunit recombinant vaccine..

Techniques: Binding Assay

COVID-19 vaccine candidates in phase 1–3 clinical trial as per 15 November 2021 [ <xref ref-type= 56 ]." width="100%" height="100%">

Journal: Vaccines

Article Title: A Narrative Review of COVID-19 Vaccines

doi: 10.3390/vaccines10010062

Figure Lengend Snippet: COVID-19 vaccine candidates in phase 1–3 clinical trial as per 15 November 2021 [ 56 ].

Article Snippet: 83 , SARS-CoV-2 Protein Subunit Recombinant Vaccine , Biofarma , Protein subunit , Indonesia , 1/2 , NCT05067894 , Indonesia , 780 , November 2021–March 2022 , Safety (phase I) and immunogenicity (phase II) of the SARS-CoV-2 protein subunit recombinant vaccine..

Techniques: Plasmid Preparation, Injection, Infection, Recombinant, Polymerase Chain Reaction, Plaque Reduction Neutralization Test, Variant Assay, Binding Assay, Coagulation, Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, Pregnancy Test (hCG) Assay

Ongoing clinical trials for novel vaccine compounds against infectious diseases in humans in phases 1–3 listed by the FDA by the November 1, 2021 ( https://www.clinicaltrials.gov/ )

Journal: Applied Microbiology and Biotechnology

Article Title: Current view on novel vaccine technologies to combat human infectious diseases

doi: 10.1007/s00253-021-11713-0

Figure Lengend Snippet: Ongoing clinical trials for novel vaccine compounds against infectious diseases in humans in phases 1–3 listed by the FDA by the November 1, 2021 ( https://www.clinicaltrials.gov/ )

Article Snippet: COVID-19 , NCT04760743 , 2020-12-17 , Recombinant Spike protein subunit vaccine , I (P) , SK bioscience Co., Ltd.

Techniques: Clinical Proteomics, Control, Recombinant, Produced, Synthesized, Plasmid Preparation, Liposomes, Vaccines

Coalition for Epidemic Preparedness Innovations Vaccine-Development Partnerships up to March 2019

Journal: Epidemiologic Reviews

Article Title: CEPI: Driving Progress Toward Epidemic Preparedness and Response

doi: 10.1093/epirev/mxz012

Figure Lengend Snippet: Coalition for Epidemic Preparedness Innovations Vaccine-Development Partnerships up to March 2019

Article Snippet: Profectus Biosciences, Emergent, and PATH , $25 million to develop a recombinant subunit protein vaccine against Nipah virus , May 2018.

Techniques: Bioprocessing, Virus, Plasmid Preparation, Recombinant, Modification, Clinical Proteomics, Immunopeptidomics, Vaccines